Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
Globe Newswire (Thu, 14-May 8:00 AM ET)
Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream
Globe Newswire (Wed, 6-May 7:00 AM ET)
Clene Announces $7 Million Underwritten Offering of Common Stock
Globe Newswire (Tue, 5-May 8:45 AM ET)
Clene to Present at Upcoming May Conferences
Globe Newswire (Tue, 5-May 8:00 AM ET)
Presenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live stream
Globe Newswire (Tue, 5-May 7:00 AM ET)
FDA Opens Door for Clene’s Accelerated ALS Therapy Approval—What’s the Big Deal for CLNN?
Market Chameleon (Mon, 4-May 5:56 AM ET)
Clene’s Fast Track with FDA Accelerates ALS Drug CNM-Au8 Toward Approval—NfL Biomarker at the Center
Market Chameleon (Mon, 4-May 4:35 AM ET)
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
Globe Newswire (Mon, 4-May 8:00 AM ET)
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Statistically Significant ALS Biomarker Results Boost CNM-Au8’s Accelerated Approval Prospects
Market Chameleon (Wed, 3-Dec 3:58 AM ET)
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene trades on the NASDAQ stock market under the symbol CLNN.
As of June 12, 2026, CLNN stock price climbed to $5.84 with 77,961 million shares trading.
CLNN has a beta of 2.88, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.07 to the broad based SPY ETF.
CLNN has a market cap of $74.63 million. This is considered a Micro Cap stock.
Last quarter Clene reported $15,000 in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-20,064 and missed earnings estimates by -$.03.
In the last 3 years, CLNN traded as high as $21.80 and as low as $2.28.
The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.
CLNN has outperformed the market in the last year with a return of +39.0%, while the SPY ETF gained +24.6%. However, in the most recent history, CLNN shares have underperformed the stock market with its stock returning +4.7% in the last 3 month period and -12.8% for the last 2 week period, while SPY has returned +9.9% and -1.7%, respectively.
CLNN support price is $5.24 and resistance is $5.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.
